Venous thrombosis after acute spinal cord injury

Cost analysis of prophylaxis guidelines

William E. Wade, Marie Chisholm-Burns

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: Venous thrombosis and pulmonary embolisms are major complications associated with acute spinal cord injury. The purpose of this study was to perform a cost analysis on the two pharmacoprophylaxis regimens suggested for deep vein thrombosis prophylaxis in this population. Methods: Efficacy and safety data were obtained from the literature. Results: Results of the cost analysis demonstrates that adjusted dose unfractionated heparin produces a cost savings over enoxaparin at 30 mg every 12 hr. Conclusion: Further studies are needed to determine the most cost-effective therapy for preventing deep vein thrombi in this population.

Original languageEnglish (US)
Pages (from-to)504-508
Number of pages5
JournalAmerican Journal of Physical Medicine and Rehabilitation
Volume79
Issue number6
DOIs
StatePublished - Nov 2000
Externally publishedYes

Fingerprint

Spinal Cord Injuries
Venous Thrombosis
Guidelines
Costs and Cost Analysis
Enoxaparin
Cost Savings
Pulmonary Embolism
Population
Heparin
Veins
Thrombosis
Safety
Therapeutics

All Science Journal Classification (ASJC) codes

  • Rehabilitation
  • Health Professions(all)
  • Orthopedics and Sports Medicine
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Venous thrombosis after acute spinal cord injury : Cost analysis of prophylaxis guidelines. / Wade, William E.; Chisholm-Burns, Marie.

In: American Journal of Physical Medicine and Rehabilitation, Vol. 79, No. 6, 11.2000, p. 504-508.

Research output: Contribution to journalArticle

@article{ce8fc73b12c7471b85ea71393d4adfab,
title = "Venous thrombosis after acute spinal cord injury: Cost analysis of prophylaxis guidelines",
abstract = "Objective: Venous thrombosis and pulmonary embolisms are major complications associated with acute spinal cord injury. The purpose of this study was to perform a cost analysis on the two pharmacoprophylaxis regimens suggested for deep vein thrombosis prophylaxis in this population. Methods: Efficacy and safety data were obtained from the literature. Results: Results of the cost analysis demonstrates that adjusted dose unfractionated heparin produces a cost savings over enoxaparin at 30 mg every 12 hr. Conclusion: Further studies are needed to determine the most cost-effective therapy for preventing deep vein thrombi in this population.",
author = "Wade, {William E.} and Marie Chisholm-Burns",
year = "2000",
month = "11",
doi = "10.1097/00002060-200011000-00003",
language = "English (US)",
volume = "79",
pages = "504--508",
journal = "American Journal of Physical Medicine and Rehabilitation",
issn = "0894-9115",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Venous thrombosis after acute spinal cord injury

T2 - Cost analysis of prophylaxis guidelines

AU - Wade, William E.

AU - Chisholm-Burns, Marie

PY - 2000/11

Y1 - 2000/11

N2 - Objective: Venous thrombosis and pulmonary embolisms are major complications associated with acute spinal cord injury. The purpose of this study was to perform a cost analysis on the two pharmacoprophylaxis regimens suggested for deep vein thrombosis prophylaxis in this population. Methods: Efficacy and safety data were obtained from the literature. Results: Results of the cost analysis demonstrates that adjusted dose unfractionated heparin produces a cost savings over enoxaparin at 30 mg every 12 hr. Conclusion: Further studies are needed to determine the most cost-effective therapy for preventing deep vein thrombi in this population.

AB - Objective: Venous thrombosis and pulmonary embolisms are major complications associated with acute spinal cord injury. The purpose of this study was to perform a cost analysis on the two pharmacoprophylaxis regimens suggested for deep vein thrombosis prophylaxis in this population. Methods: Efficacy and safety data were obtained from the literature. Results: Results of the cost analysis demonstrates that adjusted dose unfractionated heparin produces a cost savings over enoxaparin at 30 mg every 12 hr. Conclusion: Further studies are needed to determine the most cost-effective therapy for preventing deep vein thrombi in this population.

UR - http://www.scopus.com/inward/record.url?scp=0034326263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034326263&partnerID=8YFLogxK

U2 - 10.1097/00002060-200011000-00003

DO - 10.1097/00002060-200011000-00003

M3 - Article

VL - 79

SP - 504

EP - 508

JO - American Journal of Physical Medicine and Rehabilitation

JF - American Journal of Physical Medicine and Rehabilitation

SN - 0894-9115

IS - 6

ER -